Work

AML-117: A Phase 1b Study of Selinexor and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Year: 2025

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)01626-x

Authors: Somedeb Ball, Michael T. Byrne, Melissa A. Fischer, Farrukh T. Awan, Benjamin K. Tomlinson, Tess Stopczynski, Lokesh Patil, Christine J. Gu, Chris Leonardi, Katherine J. Walsh, Gregory Dan Ayers, Ashwin Kishtagari, Kateryna Fedorov, Markus D. Lacher, Joseph Wagner, Sanjay R. Mohan, Michael R. Savona

Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Tennessee Oncology, The University of Texas Southwestern Medical Center, University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, Notable Labs (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413809968

Cites:

Cited by: 1

Related to: 10